A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults With Advanced Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs AT03 65 (Primary)
Indications Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Axcynsis Therapeutics

05 Feb 2025 Status changed from planning to not yet recruiting.
28 Jan 2025 New trial record
15 Jan 2025 According to an Axcynsis Therapeutics media release, company plans to initiate a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in the US in the first quarter of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com